RG 6312
Alternative Names: RG-6312; RO-7303359Latest Information Update: 03 Jan 2024
At a glance
- Originator Roche
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Age-related macular degeneration
Most Recent Events
- 03 Jan 2024 Phase-I clinical trials in Age-related macular degeneration in USA (Intravitreous) (Roche Genentech Pipeline, January 2024)
- 26 Apr 2023 Discontinued - Phase-I for Age-related macular degeneration in USA (Intravitreous), prior to April 2023 (Roche pipeline, June 2023)
- 04 Jan 2023 Hoffmann-La Roche completes a phase Ia trial in Age-related macular degeneration in USA (Intravitreous) (NCT04615325)